Across TCGA pan-cancer cohorts, SUMO3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUMO3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SUMO3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SUMO3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, COAD, and CCRCC are the cancer types where SUMO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	0.963	0.718	.012	35	view →
COAD	DFS	Median	All	0.891	1.000	.037	12	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	11	view →
GBM	OS	Median	All	0.666	0.859	.012	4	view →
LSCC	DFS	Quartile	II,III,IV	0.493	0.833	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SUMO3 tumor-vs-normal RNA expression · all SUMO3 data types